Table 1 Patients’ characteristics
Feature | No | % |
|---|---|---|
Sex | ||
 Female | 29 | 52,7 |
 Male | 26 | 47,3 |
AJCC Stage (TNM) | ||
 IIB (T1-3, pN1, M0) | 36 | 65,45 |
 III | 14 | 25,45 |
 (T1-3, pN2, M0) | 11 | 20,0 |
 (T4, any-N, M0) | 3 | 5,5 |
 IV (any-T, any-N, M1) | 5 | 9,1 |
First treatment | ||
 Neoadjuvant plus surgery | 14 | 25,5 |
 Neoadjuvant, no surgery | 6 | 10,9 |
 Surgery plus adjuvant | 13 | 23,6 |
 Surgery, no adjuvant | 12 | 21,8 |
 No surgery, no therapy | 10 | 18,2 |
1st line chemotherapy | ||
 None | 29 | 52,7 |
 Gemcitabine-based | 20 | 36,4 |
 Capecitabine | 5 | 9,1 |
 FOLFIRINOX | 1 | 1,8 |